Moderna, Inc. · NASDAQ:MRNA

Moderna — Investor Day (November 2026)

183 slides from Moderna's investor day presentation, Nov 12, 2026

  1. Slide 1: Analyst Day 2026

    Slide 1: Analyst Day 2026

    Analyst Day 2026 November 12, 2026 © 2026 Moderna, Inc. All rights reserved.

  2. Slide 2: Forward-looking statement

    Slide 2: Forward-looking statement

    Forward-looking statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential of Moderna's mRNA platform; Moderna's ability to execute on its next phase of growth a

  3. Slide 3: Introduction

    Slide 3: Introduction

    Introduction Stéphane Bancel Chief Executive Officer 3 © 2026 Moderna, Inc. All rights reserved.

  4. Slide 4: mRNA is nature's information molecule

    Slide 4: mRNA is nature's information molecule

    mRNA is nature's information molecule, carrying instructions to make proteins DNA mRNA Protein 4 © 2026 Moderna, Inc. All rights reserved.

  5. Slide 5: Moderna was founded on the idea to use mRNA to create new medicines

    Slide 5: Moderna was founded on the idea to use mRNA to create new medicines

    Moderna was founded on the idea to use mRNA to create new medicines for patients 5 © 2026 Moderna, Inc. All rights reserved.

  6. Slide 6: Like computers use binary code, biology uses mRNA's four-letter code

    Slide 6: Like computers use binary code, biology uses mRNA's four-letter code

    Like computers use binary code, biology uses mRNA’s four-letter code to instruct cells Computers use Life uses a a binary system quaternary system 6 © 2026 Moderna, Inc. All rights reserved.

  7. Slide 7: Building a platform company

    Slide 7: Building a platform company

    Because mRNA is an information molecule, we had the unique opportunity to build a platform company mRNA science Delivery science Manufacturing Design and engineer Deliver mRNA Produce mRNA mRNA instructions into cells medicines at scale Moderna’s mRNA platform 7 © 2026 Moderna, Inc. All rights reser

  8. Slide 8: Our platform enables multiple modalities

    Slide 8: Our platform enables multiple modalities

    Our platform enables multiple modalities, each with the potential to create families of medicines Proof-of-concept data from sentinel programs de-risk modalities and can accelerate development plans By combining the components of our mRNA platform, we create modalities: groups of potential mRNA medi

  9. Slide 9: Unique properties of mRNA create advantages for drug development

    Slide 9: Unique properties of mRNA create advantages for drug development

    The unique properties of mRNA create important advantages for drug development 1 Large opportunity to address unmet need 2 Higher efficiency in R&D 3 Rapid development 4 Greater capital efficiency 9 © 2026 Moderna, Inc. All rights reserved.

  10. Slide 10: Areas where mRNA can deliver transformative patient benefit

    Slide 10: Areas where mRNA can deliver transformative patient benefit

    We are focused on areas where mRNA can deliver transformative patient benefit Infectious disease Individualized Rare genetic vaccines cancer treatments liver diseases First fundamentally new vaccine Potential to move beyond the Ability to reach intracellular protein technology platform in decades PD

  11. Slide 11: Potential to create durable franchises

    Slide 11: Potential to create durable franchises

    Our differentiated vaccines and investigational medicines have the potential to create durable franchises Infectious disease Individualized Rare genetic vaccines cancer treatments liver diseases Repeatable platform across Individualized by design; High unmet need; many pathogens proprietary algorith

  12. Slide 12: We invest across multiple horizons

    Slide 12: We invest across multiple horizons

    We invest across multiple horizons to drive near-term growth and long-term innovation Horizon 4 Inventing new technology building blocks Horizon 3 To unlock future modalities New modalities Potential to advance to first-in-human clinical trials in the mid-term Horizon 2 Emerging modalities Sales In

  13. Slide 13: AI is accelerating innovation and transforming how we work

    Slide 13: AI is accelerating innovation and transforming how we work

    AI is accelerating innovation and transforming how we work across Moderna Lucy AI-enabled ways of working Connecting AI, automation, experimentation, and AI, automation, and other technology to increase productivity, speed, data into a continuously improving learning system and adaptability across S

  14. Slide 14: Agenda

    Slide 14: Agenda

    Agenda Introduction Stéphane Bancel Chief Executive Officer Business Strategy Stephen Hoge, M.D. President Manufacturing Juan Andres Chief Operating Officer Financials Jamey Mock Chief Financial Officer Business Q&A Coffee Break Infectious Disease vaccines Rituparna Das, M.D. Ph.D. Head, Clinical De

  15. Slide 15: Business Strategy

    Slide 15: Business Strategy

    Business Strategy Stephen Hoge, M.D. President 15 © 2026 Moderna, Inc. All rights reserved.

  16. Slide 16: Executing on our three-year strategy; positioned for growth in 2027

    Slide 16: Executing on our three-year strategy; positioned for growth in 2027

    Executing on our three-year strategy; positioned for growth in 2027 Key developments supporting growth in 2027 mFLUSIVA approved by the U.S. FDA and Health Canada mNEXSPIKE and mCOMBRIAX/mCOFLU approved by EMA and Health Canada Mexico and Taiwan partnership execution Intismeran in adjuvant melanoma:

  17. Slide 17: 2026 revenue drivers

    Slide 17: 2026 revenue drivers

    2026 revenue drivers 2026 revenue growth of 15-25% expected to exceed original framework of up to 10% 2026 revenue outlook increased Strategic partnerships mNEXSPIKE Multi-year partnerships providing recurring revenue mNEXSPIKE’s share of Moderna retail sales1 mFLUSIVA 2027 UK Canada Australia Partn

  18. Slide 18: mFLUSIVA 2027 launch

    Slide 18: mFLUSIVA 2027 launch

    2027 growth driver mFLUSIVA 2027 launch Limited 2026 launch strengthens 2027/28 commercial position 2026 revenue outlook increased With August approval occurring after the 2026/27 contracting cycle, the limited launch is creating value for the next full season mFLUSIVA 2027 AAFP recommendation as an

  19. Slide 19: Approved respiratory portfolio in Europe

    Slide 19: Approved respiratory portfolio in Europe

    2027 growth driver Approved respiratory portfolio in Europe 2026 revenue Company positioned to capture market share as competitor contract expires outlook increased Four approved Estimated 2027 TAM Key milestone products in the EU (millions of doses) timeline mFLUSIVA 2027 EU product approvals LATAM

  20. Slide 20: Developing long-term LATAM and APAC partnerships

    Slide 20: Developing long-term LATAM and APAC partnerships

    2027 growth driver Developing long-term LATAM and APAC partnerships 2026 revenue outlook increased Mexico Taiwan Five-year agreement for COVID vaccines Multi-year tender for COVID vaccines mFLUSIVA 2027 signed in September 2026 with local awarded in December 2025 manufacturer Execution underway: Ini

  21. Slide 21: Intismeran in adjuvant melanoma

    Slide 21: Intismeran in adjuvant melanoma

    2027 growth driver Intismeran in adjuvant melanoma Phase 3 clinical study reported positive results 2026 revenue outlook increased Establishing INT as the standard of care in adjuvant melanoma mFLUSIVA 2027 Meaningful and durable benefit Phase 3 results show a 42% reduction in the risk of recurrence

  22. Slide 22: Intismeran: launch-ready infrastructure

    Slide 22: Intismeran: launch-ready infrastructure

    2027 growth driver Intismeran: launch-ready infrastructure The specialist capabilities and integrated ecosystem are in place to launch at scale 2026 revenue outlook increased Commercial and operational ecosystem Commercial A high-science specialist commercial model and integrated partnership end-to-

  23. Slide 23: Intismeran: Eligible U.S. market

    Slide 23: Intismeran: Eligible U.S. market

    2027 growth driver Intismeran: Eligible U.S. market A meaningful U.S. eligible population with high recurrence risk and treatment gaps 2026 revenue outlook increased High unmet need ~1 in 10 mFLUSIVA 2027 recur or die within a year of adjuvant therapy1 ~22,000 ~50%+ EU product of first recurrences i

  24. Slide 24: Balancing near-term growth with long-term R&D innovation

    Slide 24: Balancing near-term growth with long-term R&D innovation

    Balancing near-term growth with long-term R&D innovation 24

  25. Slide 25: 2027-2030: Driving financial sustainability while investing in next generation

    Slide 25: 2027-2030: Driving financial sustainability while investing in next generation

    2027-2030: Driving financial sustainability while investing in the next generation of growth Infectious disease vaccines Self-funded growth Disciplined reinvestment of commercial cash flows in infectious disease vaccine pipeline Opportunities Lyme disease EBV (mRNA-1189) Other potential future inves

  26. Slide 26: 2027-2030: Driving financial sustainability while investing in next generation

    Slide 26: 2027-2030: Driving financial sustainability while investing in next generation

    2027-2030: Driving financial sustainability while investing in the next generation of growth Infectious disease vaccines Self-funded growth Intismeran Balance sheet-funded growth Accelerated investment to drive near-term revenue growth and long-term profitability Investment opportunities Intismeran:

  27. Slide 27: 2027-2030: Driving financial sustainability while investing in next generation

    Slide 27: 2027-2030: Driving financial sustainability while investing in next generation

    2027-2030: Driving financial sustainability while investing in the next generation of growth Infectious disease vaccines Self-funded growth Intismeran Balance sheet-funded growth mRED Balance sheet-funded innovation Disciplined, multi-year investment in cutting-edge R&D Investment opportunities Canc

  28. Slide 28: Manufacturing

    Slide 28: Manufacturing

    Manufacturing Juan Andres Chief Operating Officer 28 © 2026 Moderna, Inc. All rights reserved.

  29. Slide 29: Our global infectious disease vaccines manufacturing network

    Slide 29: Our global infectious disease vaccines manufacturing network

    Our global infectious disease vaccines manufacturing network Sites across North America, Europe and Australia supporting global supply Harwell Laval UNITED KINGDOM CANADA Contract manufacturing partner Norwood UNITED STATES Clayton AUSTRALIA 29 © 2026 Moderna, Inc. All rights reserved.

  30. Slide 30: Our global infectious disease vaccines manufacturing network

    Slide 30: Our global infectious disease vaccines manufacturing network

    Our global infectious disease vaccines manufacturing network Sites across North America, Europe and Australia supporting global supply Harwell Laval UNITED KINGDOM CANADA Contract manufacturing partner Norwood UNITED STATES Strategic Partnerships Moderna-built and managed facilities under long-term

  31. Slide 31: Marlborough: Purpose-built for intismeran

    Slide 31: Marlborough: Purpose-built for intismeran

    Marlborough: Purpose-built for intismeran Harwell Laval UNITED KINGDOM CANADA Contract manufacturing partner Norwood UNITED STATES Marlborough UNITED STATES Clayton AUSTRALIA 31 © 2026 Moderna, Inc. All rights reserved.

  32. Slide 32: Marlborough: Purpose-built for intismeran

    Slide 32: Marlborough: Purpose-built for intismeran

    Marlborough: Purpose-built for intismeran Facility Design  Built for end-to-end operations with speed, scalability, and flexibility  Designed with expandable capacity Innovation & Efficiency  Incorporates digital automation, robotics, and smart skid design  Enables lower production costs and gre

  33. Slide 33: Marlborough will be the global supply site for intismeran

    Slide 33: Marlborough will be the global supply site for intismeran

    In 2027, Marlborough will be the global supply site for intismeran Site became GMP-ready in Aug 2025 and began supplying clinical study material Marlborough has latest generation manufacturing skids and lean end-to-end workflow1 Site design allows phased addition of capacity, supplying up to tens of

  34. Slide 34: Bringing intismeran to each patient

    Slide 34: Bringing intismeran to each patient

    Bringing intismeran to each patient is a product of speed, precision, and collaboration 34 © 2026 Moderna, Inc. All rights reserved.

  35. Slide 35: 3 structural levers strengthen our ability to scale efficiently

    Slide 35: 3 structural levers strengthen our ability to scale efficiently

    3 structural levers strengthen our ability to scale efficiently Compact, flexible equipment Automation Disciplined capacity expansion New technologies with material Utilization of robotics and Fixed cost absorption improves as efficiencies enable us to use agentic operations drives demand fills inst

  36. Slide 36: Smaller process footprints enable greater manufacturing capacity

    Slide 36: Smaller process footprints enable greater manufacturing capacity

    Smaller process footprints enable greater intismeran manufacturing capacity Process Generation 1 Process Generation 2 Process Generation 3 Used for clinical manufacturing Transition to commercial Prototype design Site Norwood 2019 Marlborough 2026 Marlborough Supply Clinical Clinical & commercial Cl

  37. Slide 37: Automation-driven productivity offsets demand growth

    Slide 37: Automation-driven productivity offsets demand growth

    Automation-driven productivity offsets demand growth and maintains COGS discipline Automation Predictive Analytics Agentic AI Fully digitized batch records Enabling insights, task Using AI to perform and automated material coordination, and scheduling, augment handling and cleaning through KPI track

  38. Slide 38: Modular production units enable disciplined capacity growth

    Slide 38: Modular production units enable disciplined capacity growth

    Modular production units enable disciplined capacity growth Phased build-out aligns capacity to demand while enabling staged investment and innovation Production unit 1 Currently operational; capacity sufficient for commercial launch and increasing demand Production units 2-7 Timing of activation as

  39. Slide 39: Clinical program driving commercial-scale individualized manufacturing

    Slide 39: Clinical program driving commercial-scale individualized manufacturing

    Our clinical development program is already driving commercial-scale individualized manufacturing ~5,000+ enrolled patients across studies* Multi-study Multi-tumor At commercial scale Broad clinical Across multiple Production and development portfolio cancer types delivery *Enrolled patients for stu

  40. Slide 40: Manufacturing: Key takeaways

    Slide 40: Manufacturing: Key takeaways

    Manufacturing: Key takeaways Global reach Specialized capabilities Disciplined scalability Established network supports Purpose-built infrastructure enables Efficient operating model supports infectious disease vaccine supply individualized manufacturing growth across modalities 40 © 2026 Moderna, I

  41. Slide 41: Financials

    Slide 41: Financials

    Financials Jamey Mock Chief Financial Officer 41 © 2026 Moderna, Inc. All rights reserved.

  42. Slide 42: Agenda

    Slide 42: Agenda

    Agenda Review of New Financial 2025 midterm framework Analyst Day objectives objectives 42 © 2026 Moderna, Inc. All rights reserved.

  43. Slide 43: Key takeaways from Analyst Day 2025 financial objectives

    Slide 43: Key takeaways from Analyst Day 2025 financial objectives

    Key takeaways from Analyst Day 2025 financial objectives 43 © 2026 Moderna, Inc. All rights reserved.

  44. Slide 44: Analyst Day 2025: Objective review

    Slide 44: Analyst Day 2025: Objective review

    Analyst Day 2025: Objective review Poised to deliver up to 10% revenue growth in 2026 2026 report card with multiple growth opportunities in 2027 and beyond Revenue 2026 revenue growth of 15-25% expected to exceed original framework of up to 10% 44 © 2026 Moderna, Inc. All rights reserved.

  45. Slide 45: Analyst Day 2025: Objective review

    Slide 45: Analyst Day 2025: Objective review

    Analyst Day 2025: Objective review Driving gross margin1 expansion over coming years 2026 report card (10+ percentage points over 3 years) Revenue 2026 revenue growth of 15-25% expected to exceed original framework of up to 10% Gross margins On track to achieve 10 point gross margin expansion in one

  46. Slide 46: Analyst Day 2025: Objective review

    Slide 46: Analyst Day 2025: Objective review

    Analyst Day 2025: Objective review Evolving R&D investments to diversify further into oncology 2026 report card Revenue 2026 revenue growth of 15-25% expected to exceed original framework of up to 10% Gross margins On track to achieve 10 point gross margin expansion in one year Evolve R&D investment

  47. Slide 47: Analyst Day 2025: Objective review

    Slide 47: Analyst Day 2025: Objective review

    Analyst Day 2025: Objective review Reducing 2027 projected cash costs1 to $3.5-3.9 billion and targeting 2028 cash breakeven 2026 report card Revenue 2026 revenue growth of 15-25% expected to exceed original framework of up to 10% Gross margins On track to achieve 10 point gross margin expansion in

  48. Slide 48: Analyst Day 2025: Objective review

    Slide 48: Analyst Day 2025: Objective review

    Analyst Day 2025: Objective review Confident in strong financial framework with enhanced liquidity 2026 report card Revenue 2026 revenue growth of 15-25% expected to exceed original framework of up to 10% Undrawn from Ares credit facility Gross margins On track to achieve 10 point gross margin expan

  49. Slide 49: Agenda

    Slide 49: Agenda

    Agenda Review of New Financial 2025 midterm framework Analyst Day objectives objectives 49 © 2026 Moderna, Inc. All rights reserved.

  50. Slide 50: Midterm financial objectives

    Slide 50: Midterm financial objectives

    Midterm financial objectives Build upon renewed growth Improve infectious disease vaccines profitability Continue disciplined capital allocation in oncology and emerging pipeline Maintain a strong balance sheet 50 © 2026 Moderna, Inc. All rights reserved.

  51. Slide 51: Growth momentum continues into 2027

    Slide 51: Growth momentum continues into 2027

    BUILD UPON RENEWED GROWTH Growth momentum continues into 2027 Continued growth 2026 growth drivers continue to contribute in 2027 Additional opportunities New growth drivers primarily from infectious disease products and potential intismeran launch 2027 financial framework will be shared at 4Q call

  52. Slide 52: Multiple levers to improve infectious disease profitability

    Slide 52: Multiple levers to improve infectious disease profitability

    IMPROVE INFECTIOUS DISEASE VACCINES PROFITABILITY Multiple levers to improve infectious disease profitability 2026 expectations Key driver(s) Revenue1 ~$2.3B Multiple growth opportunities in 2027 and beyond Improving volume leverage, productivity, Gross margin1,2 65% automation, procurement R&D3 ~$1

  53. Slide 53: Moderna logistics control tower

    Slide 53: Moderna logistics control tower

    IMPROVE INFECTIOUS DISEASE VACCINES PROFITABILITY BSMA Innovation Award Moderna logistics control tower Protect product value and supply continuity from visibility to protective action 1 2 3 4 See Sense Predict Act Global network visibility Product integrity monitoring Live risk intelligence Proacti

  54. Slide 54: Clinical readouts to guide capital allocation

    Slide 54: Clinical readouts to guide capital allocation

    CONTINUE DISCIPLINED CAPITAL ALLOCATION IN ONCOLOGY AND EMERGING PIPELINE Clinical readouts to guide capital allocation Potential investments in oncology and emerging pipeline Total Moderna cash costs outlook Including infectious disease programs and COGS Potential increased investment range enabled

  55. Slide 55: Refinanced Ares credit facility with improved terms

    Slide 55: Refinanced Ares credit facility with improved terms

    MAINTAIN A STRONG BALANCE SHEET Refinanced Ares credit facility with improved terms • Extends maturity New Ares credit facility terms by 1 year to 2031 Original Terms Updated Terms • Extends cutoff for Total Size $1.5B No change undrawn tranche Maturity Nov 2030 Nov 2031 to 2029 Initial Draw $0.6B N

  56. Slide 56: New midterm objectives

    Slide 56: New midterm objectives

    New midterm objectives Build upon renewed growth Improve infectious disease vaccines profitability Continue disciplined capital allocation in oncology and emerging pipeline Maintain a strong balance sheet 56 © 2026 Moderna, Inc. All rights reserved.

  57. Slide 57: Business Q&A

    Slide 57: Business Q&A

    Business Q&A 57 © 2026 Moderna, Inc. All rights reserved.

  58. Slide 58: Coffee break

    Slide 58: Coffee break

    Coffee break Presentation resumes in 15 minutes © 2026 Moderna, Inc. All rights reserved.

  59. Slide 59: Infectious disease vaccines

    Slide 59: Infectious disease vaccines

    Infectious disease vaccines Rituparna Das, M.D. Ph.D. Head, Clinical Development, Infectious Diseases, Rare Diseases, and Therapeutics 59 © 2026 Moderna, Inc. All rights reserved.

  60. Slide 60: From clinical trials to real-world impact

    Slide 60: From clinical trials to real-world impact

    From clinical trials to real-world impact Real-world evidence complements clinical trials by evaluating vaccine effectiveness, durability, and impact across diverse populations and evolving epidemiologic conditions Demonstrates Tracks durability Provides evidence in Informs vaccine real-world impact

  61. Slide 61: Section overview

    Slide 61: Section overview

    Section overview Real-world evidence data COVID-19 vaccines Estimation of mRNA-1283 vs BNT162b2 Vaccine Effectiveness in Older US Veterans Effectiveness of 2025-2026 mRNA-1283 and BNT162b2 against COVID-19–related Hospitalizations and Medically attended COVID-19 Among Adults Aged ≥65 years in the Un

  62. Slide 62: Real-world evidence data: COVID-19 vaccines

    Slide 62: Real-world evidence data: COVID-19 vaccines

    Real-world evidence data COVID-19 vaccines © 2026 Moderna, Inc. All rights reserved.

  63. Slide 63: Estimation of mRNA-1283 vs BNT162b2 Vaccine Effectiveness in Older US Veterans

    Slide 63: Estimation of mRNA-1283 vs BNT162b2 Vaccine Effectiveness in Older US Veterans

    COVID vaccines: Real-world evidence Estimation of mRNA-1283 vs BNT162b2 Vaccine Effectiveness in Older US Veterans Kevin W. McConeghy, PharmD, PhD¹,²; Benjamin Skov, PharmD¹; Frank DeVone, MS¹; Amanda Wilson, PhD³; Andre Araujo, PhD³; Nevena Vicic, MSc³; Ekkehard Beck, PhD³; Miao Jiang, PhD³; Emily

  64. Slide 64: Study design

    Slide 64: Study design

    Study design Retrospective matched cohort study using a target trial emulation framework to compare mRNA-1283 vs BNT162b2 in VHA adults ≥65 years Data source Study design VHA electronic health record, including VA Corporate Data Warehouse and linked inpatient, outpatient, laboratory, pharmacy immuni

  65. Slide 65: Selected baseline characteristics

    Slide 65: Selected baseline characteristics

    Selected baseline characteristics Retrospective active-comparator matched* cohort study emulating a pragmatic head-to-head randomized trial using VHA EHR data mRNA-1283 BNT162b2 Selected Baseline Characteristics‡ n=55,349 n=239,150 Age (years), mean (SD) 77.70 (6.71) 76.80 (6.70) Eligibility ≥75 Yea

  66. Slide 66: Consistent effectiveness advantage for mRNA-1283 over BNT162b2 in older adults

    Slide 66: Consistent effectiveness advantage for mRNA-1283 over BNT162b2 in older adults

    Real-world evidence demonstrated a consistent effectiveness advantage for mRNA-1283 over BNT162b2 LP.8.1 in older adults Cumulative Incidence, % mRNA-1283 BNT162b2 Adjusted Comparative VE║, % (95% CI) n=55,349 n=239,150 Medically-attended† (composite) 0.16 0.28 35.9% Hospitalization 0.02 0.05 47.0%

  67. Slide 67: Study limitations

    Slide 67: Study limitations

    Study limitations Residual Confounding • Residual confounding may remain despite matching and weighting • Potential unmeasured factors include undocumented prior infection and facility-level vaccine availability Interpretation Across Studies • Differences across studies should be interpreted cautiou

  68. Slide 68: Key takeaways

    Slide 68: Key takeaways

    Key takeaways mRNA-1283 was The highest comparative Exploratory MACE associated with lower VE was observed for hospitalization results COVID-19 outcome hospitalization with favored mRNA-1283 and incidence and positive COVID-19 warrant further evaluation comparative VE vs BNT162b2 in VHA adults ≥65 y

  69. Slide 69: Effectiveness of 2025-2026 mNEXSPIKE and BNT162b2 against COVID-19 outcomes

    Slide 69: Effectiveness of 2025-2026 mNEXSPIKE and BNT162b2 against COVID-19 outcomes

    COVID vaccines: Real-world evidence Effectiveness of 2025-2026 mNEXSPIKE (mRNA-1283) and BNT162b2 COVID-19 vaccines against COVID-19–related hospitalizations and medically attended COVID-19 among adults aged ≥65 years in the United States Nevena Vicic, Alina Bogdanov, Heather Hensler, Taylor Ryan, N

  70. Slide 70: Three complementary real-world studies in independent U.S. data sources

    Slide 70: Three complementary real-world studies in independent U.S. data sources

    Three complementary real-world studies in independent U.S. data sources 01 02 03 Veradigm EHR–Claims1 Optum’s de-identified Medicare FFS3 Early insight into Clinformatics® Data Largest, nationally effectiveness of mRNA Mart Database2 representative COVID-19 vaccines Replication and durability popula

  71. Slide 71: Study design: Retrospective matched cohort study

    Slide 71: Study design: Retrospective matched cohort study

    Veradigm EHR–Claims 1 Study design: Retrospective matched cohort study Objective: to estimate the early effectiveness of 2025–2026 updated COVID-19 vaccines in adults aged ≥65 years Data source Veradigm EHR linked to Komodo Health claims¹ Study design in adults aged ≥65 years Vaccination intake peri

  72. Slide 72: Study population: Baseline characteristics

    Slide 72: Study population: Baseline characteristics

    Veradigm EHR–Claims 1 Study population: Baseline characteristics EHR, electronic health records; SD, standard deviation; SMD, standardized mean difference Eligibility criteria *Centers for Disease Control and Prevention Underlying Conditions for Higher Risk for Severe COVID-19. • ≥1 year of continuo

  73. Slide 73: Observed vaccine effectiveness against hospitalization with documented COVID-19

    Slide 73: Observed vaccine effectiveness against hospitalization with documented COVID-19

    Veradigm EHR–Claims 1 Observed vaccine effectiveness against hospitalization with documented COVID-19 during the 2025–26 season Hospitalization with COVID-19 Medically attended COVID-19 Incidence, % (n) Incidence, % (n) Adjusted VE, % Adjusted VE, % Age group Vaccinated Unexposed Age group Vaccinate

  74. Slide 74: Three complementary real-world studies in independent U.S. data sources

    Slide 74: Three complementary real-world studies in independent U.S. data sources

    Three complementary real-world studies in independent U.S. data sources 01 02 03 Veradigm EHR–Claims1 Optum’s de-identified Medicare FFS3 Early insight into Clinformatics® Data Largest, nationally effectiveness of mRNA Mart Database2 representative COVID-19 vaccines Replication and durability popula

  75. Slide 75: Study Design: Retrospective matched cohort

    Slide 75: Study Design: Retrospective matched cohort

    Optum’s Clinformatics® Data Mart Database 2 Study Design: Retrospective matched cohort Objective: Estimate the effectiveness of mRNA-1283 in adults aged 18+ years Data source + population Optum® CDM, Adults ≥18 years Study design Vaccination intake period Aug 28, 2025 – Apr 30, 2026 (vaccinations th

  76. Slide 76: Study population: Baseline characteristics

    Slide 76: Study population: Baseline characteristics

    Optum’s Clinformatics® Data Mart Database 2 Study population: Baseline characteristics Baseline mRNA-1283 Unexposed ASD ASD All measured baseline characteristics (n=384,652) (n=384,652) pre post characteristics were well Age, mean (SD) 74.3 (9.58) 74.3 (9.75) 0.006 0.000 balanced after weighting Fem

  77. Slide 77: mRNA-1283 vaccine effectiveness by age group and time since vaccination

    Slide 77: mRNA-1283 vaccine effectiveness by age group and time since vaccination

    Optum’s Clinformatics® Data Mart Database 2 mRNA-1283 vaccine effectiveness against hospitalizations with COVID-19 and medically attended COVID-19: by age group and time since vaccination Hospitalization with COVID-19 Medically attended COVID-19 Incidence, % (n) Incidence, % (n) Adjusted VE, % Vacci

  78. Slide 78: Three complementary real-world studies in independent U.S. data sources

    Slide 78: Three complementary real-world studies in independent U.S. data sources

    Three complementary real-world studies in independent U.S. data sources 01 02 03 Veradigm EHR–Claims1 Optum’s de-identified Medicare FFS3 Early insight into Clinformatics® Data Largest, nationally effectiveness of mRNA Mart Database2 representative COVID-19 vaccines Replication and durability popula

  79. Slide 79: Study design: Retrospective matched cohort

    Slide 79: Study design: Retrospective matched cohort

    Medicare FFS 3 Study design: Retrospective matched cohort Objective: Estimate the effectiveness of mRNA-1283 in adults aged ≥65 years Data source + population Study design Medicare FFS, Adults ≥65 years Vaccination intake period Aug 27, 2025 – Dec 31, 2025 (vaccinations through Dec 23, 2025) COVID-1

  80. Slide 80: Study population: Baseline characteristics

    Slide 80: Study population: Baseline characteristics

    Medicare FFS 3 Study population: Baseline characteristics All measured baseline characteristics were well balanced after weighting (SMD ≤0.10) FFS, Fee-For Service; MACE, major adverse cardiovascular event; IPTW, inverse probability of treatment weighting; SD, standard deviation; ASD, absolute stand

  81. Slide 81: mRNA-1283 vaccine effectiveness against COVID-19-related outcomes

    Slide 81: mRNA-1283 vaccine effectiveness against COVID-19-related outcomes

    Medicare FFS 3 mRNA-1283 vaccine effectiveness against COVID-19-related specific and broader clinical outcomes during the 2025-2026 season COVID-19–specific outcomes Incidence rate per 10,000 person-years (95% CI) Outcomes Adjusted VE, % (95% CI) Vaccinated Unexposed 0% 20% 40% 60% 80% 100% Hospital

  82. Slide 82: mRNA-1283 real-world evidence studies recap and key takeaways

    Slide 82: mRNA-1283 real-world evidence studies recap and key takeaways

    COVID vaccines: Real-world evidence mRNA-1283 real-world evidence studies Recap and key takeaways 82

  83. Slide 83: COVID-19 vaccine effectiveness against hospitalization in U.S. adults

    Slide 83: COVID-19 vaccine effectiveness against hospitalization in U.S. adults

    COVID-19 vaccine effectiveness against hospitalization in U.S. adults: 2025–2026 season RBD/NTD encoded Full spike encoded mRNA-1283 BNT162b2 100% Veradigm Electronic Optum’s de-identified Medicare Veradigm Electronic Health Records Linked Clinformatics® Data Fee-for- Health Records Linked to Claims

  84. Slide 84: Key takeaways

    Slide 84: Key takeaways

    Key takeaways Effectiveness demonstrated Sustained effectiveness over Consistency of evidence extended follow-up In the 2025–2026 U.S. The consistency of the findings respiratory season, COVID-19 mRNA-1283 demonstrated across populations, databases, vaccines demonstrated continued effectiveness and

  85. Slide 85: Comparative effectiveness of Spikevax versus NVX-CoV2705

    Slide 85: Comparative effectiveness of Spikevax versus NVX-CoV2705

    COVID vaccines: Real-world evidence Comparative effectiveness of Spikevax (mRNA-1273) versus protein-based NVX- CoV2705 vaccination on COVID-19-related outcomes among US insured adults during 2024–2025: A retrospective matched cohort study Amanda Wilson, Ekkehard Beck, Heather Hensler, Nevena Vicic,

  86. Slide 86: 2024-2025 first COVID-19 season with divergent strain compositions and platforms

    Slide 86: 2024-2025 first COVID-19 season with divergent strain compositions and platforms

    2024-2025 marked the first COVID-19 season with divergent strain compositions and vaccine platforms available in the U.S. During the US 2024–25 season, FDA- In June 2024, VRBPAC recommended Data Gap: Limited data exist approved COVID-19 vaccines were that 2024–25 COVID-19 vaccines comparing vaccine

  87. Slide 87: Study design: Retrospective 2:1 matched cohort

    Slide 87: Study design: Retrospective 2:1 matched cohort

    Study design: Retrospective 2:1 matched cohort Matched cohort study of US insured adults 18+ (N=103,710) using Optum® CDM* Outcomes Outcomes (assessed from day 7 through up to 180 days post-vaccination) • Medically-attended COVID-19 • Hospitalization with COVID-19 Disclaimer: Interpretation of this

  88. Slide 88: Study population: Baseline characteristics

    Slide 88: Study population: Baseline characteristics

    Study population: Baseline characteristics mRNA-1273 NVX-CoV2705 Selected baseline characteristics after weighting‡ (KP.2–targeted) (JN.1–targeted) n=69,140 n=34,570 Mean age, years (SD) 66.4 (16.3) 66.2 (16.2) Exact 2:1 Matching† Age subgroup, % (n) • Age group • Sex 18−64 years 30.9% (21,386) 30.9

  89. Slide 89: Comparative vaccine effectiveness of mRNA-1273 vs. NVX-CoV2705

    Slide 89: Comparative vaccine effectiveness of mRNA-1273 vs. NVX-CoV2705

    Comparative vaccine effectiveness of mRNA-1273 vs. NVX-CoV2705 by outcome and age group Incidence, % mRNA-1273 NVX-CoV2705 Age Group Outcome Adjusted cVE, % (95% CI) (n=69,140) (n=34,570) Medically attended 31.7% 1.02 1.48 COVID-19* ≥18 years Hospitalization with 40.7% 0.09 0.14 COVID-19† Medically

  90. Slide 90: Study limitations

    Slide 90: Study limitations

    Study limitations Confounding and bias • Residual confounding from unmeasured factors may remain, including healthcare-seeking behavior, frailty, occupational exposure, and home testing practices Data limitations • Outcomes were claims-based and did not require laboratory confirmation within the dat

  91. Slide 91: Key takeaways

    Slide 91: Key takeaways

    Key takeaways In this study conducted during Similar differences were This is the first large claims- the 2024–2025 season, KP.2- observed in adults based study to directly targeted mRNA-1273 was ≥65 years of age who are compare mRNA with associated with a lower risk of known to have a higher rate o

  92. Slide 92: Real-world evidence data: RSV vaccines

    Slide 92: Real-world evidence data: RSV vaccines

    Real-world evidence data RSV vaccines © 2026 Moderna, Inc. All rights reserved.

  93. Slide 93: mRNA-1345 VE | VHA

    Slide 93: mRNA-1345 VE | VHA

    Introduction mRNA-1345 VE | VHA Adult RSV vaccines have Clinical trials showed high Real-world studies of protein- been available in the US efficacy against RSV lower based RSV vaccines have shown since 2023, but real-world respiratory tract disease, but VE of ~75%–89% against RSV- VE data are still

  94. Slide 94: Vaccine effectiveness of mRNA-1345 against RSV among US veterans

    Slide 94: Vaccine effectiveness of mRNA-1345 against RSV among US veterans

    RSV vaccine: Real-world evidence Vaccine effectiveness of mRNA-1345 against RSV-associated hospitalization and medically attended acute respiratory illness among US veterans, 2025-2026 Kevin W McConeghy, Elissa H Wilker, Frank DeVone, Benjamin Skov, Tianyu Sun, Emily Patry, E Claire Newbern, Andre B

  95. Slide 95: Two real-world evidence studies in RSV vaccines

    Slide 95: Two real-world evidence studies in RSV vaccines

    Two real-world evidence studies in RSV vaccines 01 02 Vaccine effectiveness of mRNA-1345 against RSV- RWE Across Two associated hospitalization Seasons Summary and medically attended acute respiratory illness among US veterans, 2025-2026 95 © 2026 Moderna, Inc. All rights reserved.

  96. Slide 96: Study design: Retrospective matched test-negative case control

    Slide 96: Study design: Retrospective matched test-negative case control

    mRNA-1345 Vaccine Effectiveness in U.S. Veterans’ Administration 1 Study design: Retrospective matched test-negative case control Within the VHA EHR system among adults ≥50 years Objective To evaluate mRNA-1345 VE against RSV-associated hospitalization and medically attended RSV-ARI during the 2025–

  97. Slide 97: Study population: Baseline characteristics

    Slide 97: Study population: Baseline characteristics

    mRNA-1345 Vaccine Effectiveness in U.S. Veterans’ Administration 1 Study population: Baseline characteristics Baseline characteristics were well balanced after matching, supporting comparability between RSV-positive cases and test-negative controls ARI, acute respiratory infections; CKD, chronic kid

  98. Slide 98: Estimated mRNA-1345 vaccine effectiveness in veterans ≥50 years

    Slide 98: Estimated mRNA-1345 vaccine effectiveness in veterans ≥50 years

    mRNA-1345 Vaccine Effectiveness in U.S. Veterans’ Administration 1 Estimated mRNA-1345 vaccine effectiveness against RSV-positive ARI-associated outcomes in veterans ≥50 years Matched*, Adjusted Set Cases Controls n=3,673 n=14,566 mRNA-1345 VE‡, % (95% CI) Vaccinated Unvaccinated Vaccinated Unvaccin

  99. Slide 99: Study limitations

    Slide 99: Study limitations

    mRNA-1345 Vaccine Effectiveness in U.S. Veterans’ Administration 1 Study limitations Limited precision for hospitalization estimate • Few vaccinated RSV-positive hospitalized cases were observed • Hospitalization VE suggests substantial protection, although the effect estimate was imprecise • Contin

  100. Slide 100: Key takeaways

    Slide 100: Key takeaways

    Key takeaways 1 Study provides initial real- Evaluates effectiveness in a Reductions in RSV-positive world effectiveness evidence high-risk VHA population ARI–associated hospitalizations for mRNA-1345, an mRNA- ≥50 years with comorbidities, and medically attended based RSV vaccine frailty, and encou

  101. Slide 101: Two real-world evidence studies in RSV vaccines

    Slide 101: Two real-world evidence studies in RSV vaccines

    Two real-world evidence studies in RSV vaccines 01 02 Vaccine effectiveness of mRNA-1345 against RSV- RWE Across Two associated hospitalization Seasons Summary and medically attended acute respiratory illness among US veterans, 2025-2026 101 © 2026 Moderna, Inc. All rights reserved.

  102. Slide 102: Summary of RSV vaccine effectiveness studies across two seasons

    Slide 102: Summary of RSV vaccine effectiveness studies across two seasons

    Summary of RSV vaccine effectiveness studies in the U.S. 2 across two seasons IVY Network1 VISION Network2 VHA3 KPSC4 Test-negative, Test-negative, Test-negative, Design case-control case-control Target trial emulation case-control Adults aged ≥60 with ARI Adults aged ≥60 Adults aged ≥60 with Adults

  103. Slide 103: RSV vaccine effectiveness against hospitalization across two seasons

    Slide 103: RSV vaccine effectiveness against hospitalization across two seasons

    2 RSV vaccine effectiveness against RSV-associated hospitalization across two seasons in adults aged ≥60 Overall population Follow up, Season Study Design Vaccine(s) n VE, % (95% CI) days (range) Assessed 778 92 (54–128) First 69% (52–81) Test- RSVpreF IVY Network1,* negative RSVPreF3 801 419 (357–4

  104. Slide 104: RSV vaccine effectiveness: immunocompromised subgroup analyses

    Slide 104: RSV vaccine effectiveness: immunocompromised subgroup analyses

    2 RSV vaccine effectiveness against RSV-associated hospitalization across two seasons in adults aged ≥60 Immunocompromised (IC) subgroup analyses Follow up, Season Study Design Vaccine(s) IC Status n VE, % (95% CI) days (range) Assessed 603 86 (50–127) First 74% (53–85) No IVY Test- RSVpreF 612 420

  105. Slide 105: Key takeaways

    Slide 105: Key takeaways

    Key takeaways Across multiple large US VE was generally higher earlier Subgroup analyses, including networks over two RSV seasons after vaccination, with evidence among immunocompromised (2023–24 and 2024–25), real- of waning over time, adults, generally showed lower world studies consistently parti

  106. Slide 106: Influenza vaccine RWE trial design mRNA-1010

    Slide 106: Influenza vaccine RWE trial design mRNA-1010

    Influenza vaccine RWE trial design mRNA-1010 © 2026 Moderna, Inc. All rights reserved.

  107. Slide 107: Flu vaccine (mRNA-1010) real-world evidence study

    Slide 107: Flu vaccine (mRNA-1010) real-world evidence study

    Flu vaccine (mRNA-1010) real-world evidence study Study US adults ≥65 years Population US adults ≥65 years Stage 2 ~400,000 per season Randomization 1:1 (cluster-randomized) Stage 2 Objectives Primary objective Secondary objectives • Compare vaccine efficacy of mRNA-1010 vs. 1 Compare relative vacci

  108. Slide 108: Flu + COVID combination vaccine RWE trial design mRNA-1083

    Slide 108: Flu + COVID combination vaccine RWE trial design mRNA-1083

    Flu + COVID combination vaccine RWE trial design mRNA-1083 © 2026 Moderna, Inc. All rights reserved.

  109. Slide 109: DAN-COMBO study overview

    Slide 109: DAN-COMBO study overview

    DAN-COMBO study overview Phase 4, Pragmatic, Individually-Randomized Trial (EUCT 2026-526720-49-00; NCT07790523)1,2 Data source Leverages population-based administrative health registries in Denmark and the region of Galicia, Spain to enable comprehensive ascertainment of vaccination and clinically

  110. Slide 110: AI in annual strain update

    Slide 110: AI in annual strain update

    AI in annual strain update Bill Schief, Ph.D. Vice President, Protein Design, Infectious Disease Research 110 © 2026 Moderna, Inc. All rights reserved.

  111. Slide 111: Rapid viral evolution creates a need for annual vaccine strain updates

    Slide 111: Rapid viral evolution creates a need for annual vaccine strain updates

    Rapid viral evolution creates a need for annual vaccine strain updates 4 SEASONAL VACCINES 5 ANTIGENS SPIKEVAX mRNA-1273 mNEXSPIKE mRNA-1283 mFLUSIVA mRNA-1010 mCOMBRIAX mRNA-1083 We monitor viral evolution and assess vaccine strains continuously 111 © 2026 Moderna, Inc. All rights reserved.

  112. Slide 112: Innovating seasonal vaccine updates from strain selection to manufacturing

    Slide 112: Innovating seasonal vaccine updates from strain selection to manufacturing

    Innovating seasonal vaccine updates from strain selection to manufacturing Speed Precision Scalable manufacturing Continuous monitoring and Sequence-based design Leverages our proven mRNA evaluation of emerging viral enables antigen matching manufacturing platform and strains enables timely and rapi

  113. Slide 113: Annual strain update is a company-wide effort

    Slide 113: Annual strain update is a company-wide effort

    Annual strain update is a company-wide effort 4 SEASONAL VACCINES 5 ANTIGENS COVID typically updated SPIKEVAX mNEXSPIKE mFLUSIVA mCOMBRIAX mRNA-1283 mRNA-1083 annually; influenza updated twice mRNA-1273 mRNA-1010 yearly to reflect each hemisphere 1 2 3 4 5 6 Research Technical Manufacturing Regulato

  114. Slide 114: mStrain surveillance platform

    Slide 114: mStrain surveillance platform

    mStrain surveillance platform distills thousands of circulating COVID-19 and influenza sequences into a few candidate vaccine strains What is circulating? ● Where is it spreading? How fast is it growing? ● How much immunity might it escape? mStrain | AI-enabled surveillance platform Monitor Classify

  115. Slide 115: mStrain surveillance reveals geographic distributions of circulating viruses

    Slide 115: mStrain surveillance reveals geographic distributions of circulating viruses

    mStrain surveillance reveals geographic distributions of circulating viruses Provides one input in our monitoring of potential need for regional vaccines Example: Circulating COVID-19 viral strains Source: mSTRAIN and public sources 115 © 2026 Moderna, Inc. All rights reserved.

  116. Slide 116: Tracking and modeling variant growth

    Slide 116: Tracking and modeling variant growth

    Tracking and modeling variant growth enables early identification of variants of concern Variant X Global Growth Trend 26% <1% Growth ranking Growth advantage Doubling time 1st 35% 4 weeks 116 © 2026 Moderna, Inc. All rights reserved.

  117. Slide 117: Immune-escape risk calculator informs COVID strain selection

    Slide 117: Immune-escape risk calculator informs COVID strain selection

    Immune-escape risk calculator informs COVID strain selection Machine-learning model predicts how strongly a given virus will escape from neutralizing antibodies induced by a given vaccine Method validated prospectively Example predicted escape by different across four seasons viruses for 2 different

  118. Slide 118: Agentic AI and wet lab analyses evaluate vaccine antigens

    Slide 118: Agentic AI and wet lab analyses evaluate vaccine antigens

    Agentic AI and wet lab analyses rapidly evaluate vaccine antigens for emerging strains AGENTIC AI WET LAB mStrain surveillance Structure Metrics Design alternates N I T N L C P F G E V F N A T R F A S V Y A W N R K R I S N C V Vaccine synthesis Update the variant watchlist Experimental evaluation 11

  119. Slide 119: High-throughput data and custom-trained AI models for antigen assessment

    Slide 119: High-throughput data and custom-trained AI models for antigen assessment

    We are collecting high-throughput data and building custom-trained AI models for rapid antigen assessment and adjustment Collaboration with Lila Sciences INPUT: PHYLOGENETIC SELECTION Measure mRNA-1283 Measure effects of all mutations 1 2 3 Build custom AI models 740 expression profile across divers

  120. Slide 120: Reducing time from flu strain selection to vaccine supply to 2–3 months

    Slide 120: Reducing time from flu strain selection to vaccine supply to 2–3 months

    By combining mRNA technology with our ASU process, we aim to reduce the time from flu strain selection to vaccine supply to 2–3 months ~6 - 8 months from strain selection to supply Traditional egg-based manufacturing Select and Grow virus Purify and Formulate and Lot release adapt strain in eggs ina

  121. Slide 121: Oncology therapeutics

    Slide 121: Oncology therapeutics

    Oncology therapeutics David Berman, M.D., Ph.D. Chief Development Officer 121 © 2026 Moderna, Inc. All rights reserved.

  122. Slide 122: Intismeran: Advancing individualized cancer immunotherapy

    Slide 122: Intismeran: Advancing individualized cancer immunotherapy

    Therapeutics Intismeran: Advancing individualized cancer immunotherapy © 2026 Moderna, Inc. All rights reserved.

  123. Slide 123: Immune surveillance controls emerging cancer cells

    Slide 123: Immune surveillance controls emerging cancer cells

    Immune surveillance controls emerging cancer cells Immune system detects cancer antigens Activated T cells eliminate cancer (neoantigens) Neoantigen-reactive T cells are activated Neoantigens drain to lymph node and are presented and target the cancer by antigen presenting cells (APC) to T cells Gav

  124. Slide 124: Cancers can escape immune surveillance when…

    Slide 124: Cancers can escape immune surveillance when…

    Cancers can escape immune surveillance when… APCs do not activate T cells T cells become exhausted Insufficient neoantigen processing, e.g. PD1/PDL1 presentation, or T cell activation Exhausted T cells 124 © 2026 Moderna, Inc. All rights reserved.

  125. Slide 125: Checkpoints act on T cells, but are limited by available neoantigens

    Slide 125: Checkpoints act on T cells, but are limited by available neoantigens

    Checkpoints act on T cells, but are limited by available neoantigens 125 © 2026 Moderna, Inc. All rights reserved.

  126. Slide 126: Intismeran optimizes neoantigen presentation

    Slide 126: Intismeran optimizes neoantigen presentation

    Intismeran optimizes neoantigen presentation 126 © 2026 Moderna, Inc. All rights reserved.

  127. Slide 127: How intismeran activates tumor-specific T cells

    Slide 127: How intismeran activates tumor-specific T cells

    How intismeran activates tumor-specific T cells Algorithm selects most mRNA-LNP delivers neoantigens 1 2 promising neoantigens to APCs in lymph node High neoantigen expression mRNA-LNP Neoantigen-derived peptides produced and presented in antigen presenting cell Optimal environment Activation in lym

  128. Slide 128: Intismeran autogene is the most advanced individualized neoantigen therapy

    Slide 128: Intismeran autogene is the most advanced individualized neoantigen therapy

    Intismeran autogene is the most advanced individualized neoantigen therapy in development Intismeran consists of an mRNA that encodes neoantigens designed specifically to each individual patient’s tumor mutanome and human leukocyte antigen (HLA) type 128 © 2026 Moderna, Inc. All rights reserved.

  129. Slide 129: © 2026 Moderna, Inc. All rights reserved.

    Slide 129: © 2026 Moderna, Inc. All rights reserved.

    129 © 2026 Moderna, Inc. All rights reserved.

  130. Slide 130: Many patients have recurrence despite adjuvant PD-1 inhibition

    Slide 130: Many patients have recurrence despite adjuvant PD-1 inhibition

    Despite RFS and DMFS benefit for adjuvant PD-1 inhibition in Phase 3 melanoma trials, many patients have recurrence HR 0.63 HR 0.62 (95% CI, 0.53-0.74) (95% CI, 0.50-0.76) 130 © 2026 Moderna, Inc. All rights reserved.

  131. Slide 131: Dual checkpoint blockade in adjuvant setting has failed to improve efficacy

    Slide 131: Dual checkpoint blockade in adjuvant setting has failed to improve efficacy

    Dual checkpoint blockade in the adjuvant setting has failed to improve efficacy while increasing toxicity in Phase 3 trials PD-1 + CTLA-4 PD-1 + LAG3 PD-1 + TIGIT 131 © 2026 Moderna, Inc. All rights reserved.

  132. Slide 132: INTerpath-001: Randomized, double-blind, Phase 3 trial

    Slide 132: INTerpath-001: Randomized, double-blind, Phase 3 trial

    INTerpath-001: Randomized, double-blind, Phase 3 trial 132 © 2026 Moderna, Inc. All rights reserved.

  133. Slide 133: Predefined analysis populations

    Slide 133: Predefined analysis populations

    Predefined analysis populations 133 © 2026 Moderna, Inc. All rights reserved.

  134. Slide 134: Intismeran design, manufacture, and exposure

    Slide 134: Intismeran design, manufacture, and exposure

    Intismeran design, manufacturea, and exposure • 91% of the 1137 randomized patients had the maximum 34 neoantigens identified for intismeran design • 99% of the 757 patients in the intismeran + pembrolizumab arm had their intismeran successfully manufactured • Median time to first intismeran dose wa

  135. Slide 135: Baseline characteristics

    Slide 135: Baseline characteristics

    Baseline characteristics 135 © 2026 Moderna, Inc. All rights reserved.

  136. Slide 136: Phase 3 results demonstrate a 42% reduction in risk of recurrence or death

    Slide 136: Phase 3 results demonstrate a 42% reduction in risk of recurrence or death

    Phase 3 results demonstrate a 42% reduction in the risk of recurrence or death Key takeaways First positive Phase 3 for therapeutic cancer vaccine First positive Phase 3 versus anti-PD1 in adjuvant melanoma a. Randomization stratification factors applied to all stratified analyses. 136 © 2026 Modern

  137. Slide 137: Phase 2 results demonstrate greater RFS benefit with longer follow-up

    Slide 137: Phase 2 results demonstrate greater RFS benefit with longer follow-up

    Phase 2 results demonstrate greater RFS benefit with longer follow-up Primary analysis1 3-year analysis2 5-year analysis3 Primary analysis a 3-year follow-up 5-year follow-up Phase 2 0.56 (median F/U: 23 months4) 0.51 (median F/U: 34.9 months) 0.51 (median F/U: 60.3 months) Phase 3 0.58 (median foll

  138. Slide 138: mITT analysis shows greater RFS benefit among patients treated as planned

    Slide 138: mITT analysis shows greater RFS benefit among patients treated as planned

    mITT analysis shows a greater RFS benefit among patients who received intismeran as planned Key takeaways mITT population excludes participants who did not receive at least one dose of intismeran or placebo as planned a. Randomization stratification factors applied to all stratified analyses. 138 ©

  139. Slide 139: DMFS Primary Analysis: ITT

    Slide 139: DMFS Primary Analysis: ITT

    DMFS Primary Analysis: ITT 139 © 2026 Moderna, Inc. All rights reserved.

  140. Slide 140: DMFS Sensitivity Analysis: mITT

    Slide 140: DMFS Sensitivity Analysis: mITT

    DMFS Sensitivity Analysis: mITT 140 © 2026 Moderna, Inc. All rights reserved.

  141. Slide 141: Efficacy in prespecified subgroups

    Slide 141: Efficacy in prespecified subgroups

    Efficacy in prespecified subgroups RFS and DMFS benefits observed in most subgroups 141 © 2026 Moderna, Inc. All rights reserved.

  142. Slide 142: Adverse event summary

    Slide 142: Adverse event summary

    Adverse event summary 142 © 2026 Moderna, Inc. All rights reserved.

  143. Slide 143: Safety findings consistent with known profiles of individual therapies

    Slide 143: Safety findings consistent with known profiles of individual therapies

    Safety findings were consistent with the known profiles of the individual therapies AEs of interest for intismeran were consistent with expected profile • The most common AEs in the intismeran + KEYTRUDA arm were pyrexia (52.2%), injection site pain (51.0%), and fatigue (38.5%) • AEs were generally

  144. Slide 144: Summary and conclusions

    Slide 144: Summary and conclusions

    Summary and conclusions INTerpath-001 met both the primary RFS and key secondary DMFS endpoints • Intismeran + pembrolizumab reduced the risk of recurrence or death by 42% and the risk of distant metastasis or death by 38% compared with placebo + pembrolizumab • In a modified intent-to-treat sensiti

  145. Slide 145: Beyond melanoma, unmet need remains across adjuvant cancer settings

    Slide 145: Beyond melanoma, unmet need remains across adjuvant cancer settings

    Beyond melanoma, unmet need remains across adjuvant cancer settings Estimated recurrence rate with adjuvant checkpoint inhibitors Bladder cancer ~64% Gastric/ ~33% (MIUC) recurrence rate GEJ cancer event rate at 5 years 1 at 2 years **4 ~48% Pancreatic ~74% Lung cancer recurrence rate recurrence rat

  146. Slide 146: Reasons to believe intismeran will have benefit across tumor types

    Slide 146: Reasons to believe intismeran will have benefit across tumor types

    Reasons to believe intismeran will have benefit across tumor types Activates T cells Similar activity in Large treatment effect Anti-PD1 reverses exhaustion of high and non-high High treatment effect in existing T cells whereas TMB melanoma in INT-001 bodes well for other intismeran activates new T

  147. Slide 147: Reasons to believe intismeran will have benefit across tumor types

    Slide 147: Reasons to believe intismeran will have benefit across tumor types

    Reasons to believe intismeran will have benefit across tumor types Activates T cells Similar activity in Large treatment effect Anti-PD1 reverses exhaustion of high and non-high High treatment effect in existing T cells whereas TMB melanoma in INT-001 bodes well for other intismeran activates new T

  148. Slide 148: Intismeran generates novel anti-tumor T cell responses

    Slide 148: Intismeran generates novel anti-tumor T cell responses

    Intismeran generates novel anti-tumor T cell responses Intismeran Anti-PD-1 immunotherapy Primes and activates new, neoantigen- Restores activity of existing specific T cells against the tumor tumor-reactive T cells Intismeran Anti-PD-1 Existing Newly activated blocks PD-1 exhausted novel T cells si

  149. Slide 149: Intismeran plus pembrolizumab induces more novel T cell clones

    Slide 149: Intismeran plus pembrolizumab induces more novel T cell clones

    5-year KEYNOTE-942 data, oral abstract presentation, ASCO 2026 Intismeran plus pembrolizumab induces more novel T cell clones Red line=neoantigen specific T cells 149 © 2026 Moderna, Inc. All rights reserved.

  150. Slide 150: Patients without recurrence showed greater expansion of novel T cell clones

    Slide 150: Patients without recurrence showed greater expansion of novel T cell clones

    5-year KEYNOTE-942 data, oral abstract presentation, ASCO 2026 Patients without recurrence on intismeran plus pembrolizumab showed greater expansion of novel T cell clones 150 © 2026 Moderna, Inc. All rights reserved.

  151. Slide 151: Intismeran induces neoantigen-specific T cells

    Slide 151: Intismeran induces neoantigen-specific T cells

    5-year KEYNOTE-942 data, oral abstract presentation, ASCO 2026 Intismeran induces neoantigen-specific T cells Neoantigens recognized by patient’s T cells • On average 1 of 3 selected neoantigens induce T cell response • Induces both CD4 and CD8 neoantigen reactive T cells Number of immunogenic neoan

  152. Slide 152: CD8+ and CD4+ neoantigen T cells are polyfunctional and cytotoxic

    Slide 152: CD8+ and CD4+ neoantigen T cells are polyfunctional and cytotoxic

    Phase 2 translational data, poster presentation, ASCO 2026 The CD8+ and CD4+ neoantigen T cells are polyfunctional and cytotoxic Polyfunctional Cytotoxic markers markers Intracellular cytokine staining (ICS) of neoantigen reactive T cells from patient #3 152 © 2026 Moderna, Inc. All rights reserved.

  153. Slide 153: Neoantigen-specific T cell clones detected after intismeran

    Slide 153: Neoantigen-specific T cell clones detected after intismeran

    Phase 2 translational data, poster presentation, ASCO 2026 The neoantigen-specific T cell clones detected after intismeran unt 1 l g1 Neoantigen 14;1CD8+ 8 e antigen Neoantigen 27; CD4 e antigen 7 + & CD88+ Neoantigen 28; CD4 e antigen 8 + & CD88 + e antigen 1 e antigen 7 e antigen 8 8 8 8 Multiple

  154. Slide 154: Reasons to believe intismeran will have benefit across tumor types

    Slide 154: Reasons to believe intismeran will have benefit across tumor types

    Reasons to believe intismeran will have benefit across tumor types Activates T cells Similar activity in Large treatment effect Anti-PD1 reverses exhaustion of high and non-high High treatment effect in existing T cells whereas TMB melanoma in INT-001 bodes well for other intismeran activates new T

  155. Slide 155: Subgroup analyses indicate RFS benefit across broad patient population

    Slide 155: Subgroup analyses indicate RFS benefit across broad patient population

    5-year KEYNOTE-942 data, oral abstract presentation, ASCO 2026 Subgroup analyses indicate RFS benefit is maintained across a broad patient population 155 © 2026 Moderna, Inc. All rights reserved.

  156. Slide 156: Phase 2 data strengthen confidence across multiple cancer indications

    Slide 156: Phase 2 data strengthen confidence across multiple cancer indications

    Phase 2 adjuvant melanoma data strengthen confidence in intismeran's potential across multiple cancer indications TMB cut-off Many tumor histologies are IO sensitive Red text: Checkpoint inhibitors are approved for treatment of this cancer indication * Primarily MSI-H/dMMR disease Source: Büttner R,

  157. Slide 157: Ongoing Phase 2 or Phase 3 studies in multiple indications

    Slide 157: Ongoing Phase 2 or Phase 3 studies in multiple indications

    Ongoing Phase 2 or Phase 3 studies in multiple indications Melanoma Non-small cell lung cancer MIBC NMIBC Renal cell carcinoma Gastric cancer Pancreatic cancer Red text: Checkpoint inhibitors are approved for treatment of this cancer indication * Primarily MSI-H/dMMR disease Source: Büttner R, et al

  158. Slide 158: Reasons to believe intismeran will have benefit across tumor types

    Slide 158: Reasons to believe intismeran will have benefit across tumor types

    Reasons to believe intismeran will have benefit across tumor types Activates T cells Similar activity in Large treatment effect Anti-PD1 reverses exhaustion of high and non-high High treatment effect in existing T cells whereas TMB melanoma in INT-001 bodes well for other intismeran activates new T

  159. Slide 159: Phase 3 adjuvant melanoma results show potential for added benefit

    Slide 159: Phase 3 adjuvant melanoma results show potential for added benefit

    Phase 3 in adjuvant melanoma results demonstrate the potential for added benefit with intismeran + KEYTRUDA Hazard ratios for randomized Phase 3 trials Adjuvant RCC NSCLC MIBC melanoma KEYNOTE 0542 KEYNOTE 5643 KEYNOTE 0914 AMBASSADOR TRIAL5 KEYTRUDA alone versus placebo1 0.56 0.68 0.76 0.69 Median

  160. Slide 160: Intismeran's clinical development program

    Slide 160: Intismeran's clinical development program

    Intismeran’s clinical development program Partnered with Merck Treatment in investigational arm: Ph 1 Ph 2 Ph 3 Commercial Enrollment status Clinical readouts intismeran + ADJUVANT • Data presented at ESMO 2026 Melanoma pembrolizumab Fully enrolled • Published in NEJM NSCLC pembrolizumab Fully enrol

  161. Slide 161: Cancer antigen therapies

    Slide 161: Cancer antigen therapies

    Therapeutics Cancer antigen therapies 161

  162. Slide 162: Cancer antigen therapies designed to target distinct tumor biology

    Slide 162: Cancer antigen therapies designed to target distinct tumor biology

    Cancer antigen therapies are designed to target distinct tumor biology Tumor-specific Antigens (TSAs) Tumor Associated Antigens (TAAs) Individualized Tumor Frameshift Cancer testis mutations / Overexpressed microenvironment- mutations antigens Hotspots associated Intismeran mRNA-4194 mRNA-4359 mRNA-

  163. Slide 163: Lynch Syndrome: An inherited cancer predisposition syndrome

    Slide 163: Lynch Syndrome: An inherited cancer predisposition syndrome

    Lynch Syndrome: An inherited cancer predisposition syndrome Individuals with Lynch syndrome face elevated lifetime risk of colorectal, endometrial, and other cancers Current management relies primarily on surveillance, with aspirin used by some patients as a preventive strategy to reduce colorectal

  164. Slide 164: Frameshift mutations create targetable source of cancer-specific antigens

    Slide 164: Frameshift mutations create targetable source of cancer-specific antigens

    Frameshift mutations create a potentially targetable source of cancer-specific antigens  mRNA-4194 antigens are shared across colorectal, endometrial, and gastric MSI-H tumors, supporting relevance across key Lynch-associated cancer types.  The vaccine incorporates 194 frameshift antigens to creat

  165. Slide 165: Anti-PD1 has high response rate in MSI-H/Lynch cancers

    Slide 165: Anti-PD1 has high response rate in MSI-H/Lynch cancers

    Anti-PD1 has high response rate in MSI-H/Lynch cancers Colorectal cancer 44%1 MSI-high cancers Non-colorectal cancer 33-57%2 Colorectal cancer and regression of colon polyps3 71%3 Lynch syndrome Any cancer 58%4 1. N Engl J Med. 2020 Dec 3;383(23):2207-2218 2. J Clin Oncol 2019 Nov 4;38(1):1–10 3. Eu

  166. Slide 166: mRNA-4194 designed to induce novel anti-tumor T cells

    Slide 166: mRNA-4194 designed to induce novel anti-tumor T cells

    mRNA-4194 designed to induce novel anti-tumor T cells mRNA-4194 Anti-PD-1 immunotherapy Primes and activates new frameshift Restores activity of existing neoantigen-specific T cells against the tumor tumor-reactive T cells Anti-PD-1 Existing Newly activated blocks PD-1 exhausted novel T cells signal

  167. Slide 167: Objective: Intercept cancer before it develops in Lynch Syndrome

    Slide 167: Objective: Intercept cancer before it develops in Lynch Syndrome

    Objective: Intercept cancer before it develops in people living with Lynch Syndrome Without intervention The natural progression from healthy tissue to metastatic cancer Healthy Adenoma Localized cancer Metastatic cancer 167 © 2026 Moderna, Inc. All rights reserved.

  168. Slide 168: Objective: Intercept cancer before it develops in Lynch Syndrome

    Slide 168: Objective: Intercept cancer before it develops in Lynch Syndrome

    Objective: Intercept cancer before it develops in people living with Lynch Syndrome With intervention mRNA-4194 aims to eliminate emerging malignant cells before cancer develops mRNA-4194 Activates novel T cells to recognize and eliminate emerging malignant Healthy Healthy cells. Adenoma Adenoma Loc

  169. Slide 169: FIH Phase 1 Lynch Syndrome study design

    Slide 169: FIH Phase 1 Lynch Syndrome study design

    FIH Phase 1 Lynch Syndrome study design P101 will be divided into 2 parts: Part 1 will test safety and immunogenicity & Part 2 will assess proof of biology PART 1 PART 2 Dose Escalation Dose Expansion Evaluate safety and immunogenicity Demonstrate proof of biology 4 priming doses + 3 doses at 0, 6,

  170. Slide 170: FIH part 2 designed to evaluate effect on MSI-H adenomas

    Slide 170: FIH part 2 designed to evaluate effect on MSI-H adenomas

    FIH part 2 designed to evaluate effect on MSI-H adenomas Part 2 of Phase 1 mRNA-4194 study in Lynch Syndrome 1 2 3 4 5 Baseline Eligibility 7-Month Central mRNA-4194 Colonoscopy Criteria Colonoscopy Review Screen participants • N=40 per cohort Administration of Polyps measured Colonoscopy video usin

  171. Slide 171: T cell engagers

    Slide 171: T cell engagers

    Therapeutics T cell engagers 171

  172. Slide 172: mRNA-2808 could differentiate in multiple myeloma with three disease antigens

    Slide 172: mRNA-2808 could differentiate in multiple myeloma with three disease antigens

    mRNA-2808 could differentiate in multiple myeloma as the only treatment targeting three disease antigens T-cell engager landscape in multiple myeloma Single target Two targets Three targets Bi-specific approach Expanded targeting potential 172 © 2026 Moderna, Inc. All rights reserved.

  173. Slide 173: mRNA-2808 includes distinct T-cell engagers against validated myeloma targets

    Slide 173: mRNA-2808 includes distinct T-cell engagers against validated myeloma targets

    mRNA-2808 includes distinct T-cell engagers against clinically- validated multiple myeloma targets; BCMA, GPRC5D, and FcRH5 mRNA-2808 mechanism of action  Multiplexes to overcome antigen escape, well- established resistance mechanism  Targets T cell CD3 and clinically validated tumor associated an

  174. Slide 174: mRNA-2808 phase 1/2 study ongoing in multiple myeloma

    Slide 174: mRNA-2808 phase 1/2 study ongoing in multiple myeloma

    mRNA-2808 phase 1/2 study ongoing in multiple myeloma Phase 1/2 study design and key objectives Key eligibility: Relapsed refractory multiple myeloma with prior exposure to three treatments: a proteasome inhibitor, an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD38) monocl

  175. Slide 175: mRNA-2808 demonstrates encouraging early clinical activity

    Slide 175: mRNA-2808 demonstrates encouraging early clinical activity

    mRNA-2808 demonstrates encouraging early clinical activity with a multiplexed T-cell engager approach  Abstract accepted for ASH 2026 Oral mRNA-2808 mechanism of action presentation: “Initial results from a first-in- human phase 1/2 trial of mRNA-2808, a multiplexed mRNA therapeutic encoding BCMA,

  176. Slide 176: Oncology pipeline

    Slide 176: Oncology pipeline

    Oncology pipeline 176 © 2026 Moderna, Inc. All rights reserved.

  177. Slide 177: Clinical Q&A

    Slide 177: Clinical Q&A

    Clinical Q&A 177

  178. Slide 178: Conclusion

    Slide 178: Conclusion

    Conclusion Stéphane Bancel Chief Executive Officer 178 © 2026 Moderna, Inc. All rights reserved.

  179. Slide 179: We invest across multiple horizons to drive near-term growth and long-term innovation

    Slide 179: We invest across multiple horizons to drive near-term growth and long-term innovation

    We invest across multiple horizons to drive near-term growth and long-term innovation Horizon 4 Inventing new technology Horizon 3 building blocks New modalities To unlock future modalities Potential to advance to first-in-human clinical trials in the mid-term Horizon 2 Emerging modalities Horizon 1

  180. Slide 180: Most people thought about Moderna as a COVID-19 vaccine company

    Slide 180: Most people thought about Moderna as a COVID-19 vaccine company

    Most people thought about Moderna as a COVID-19 vaccine company ID vaccines • Spikevax 180 © 2026 Moderna, Inc. All rights reserved.

  181. Slide 181: We invest across multiple horizons to drive near-term growth and long-term innovation

    Slide 181: We invest across multiple horizons to drive near-term growth and long-term innovation

    We invest across multiple horizons to drive near-term growth and long-term innovation Horizon 4 Inventing new technology Horizon 3 building blocks New modalities To unlock future modalities Potential to advance to first-in-human clinical trials in the mid-term Horizon 2 Emerging modalities Horizon 1

  182. Slide 182: © 2026 Moderna, Inc. All rights reserved.

    Slide 182: © 2026 Moderna, Inc. All rights reserved.

    182 © 2026 Moderna, Inc. All rights reserved.

  183. Slide 183: Thank you

    Slide 183: Thank you

    Thank you © 2026 Moderna, Inc. All rights reserved.

Source: company website

More decks from Moderna, Inc.

All 65 Moderna decks